Vimarsana
Biggest News Aggregation in the World

Safety Analysis Set News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safety Analysis Set. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safety Analysis Set Today - Breaking & Trending Today

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL) - Vimarsana News

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)

Published: September 7, 2022

KITE’S  CAR  T-CELL  THERAPY  TECARTUS®  (BREXUCABTAGENE  AUTOLEUCEL)  GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF  RELAPSED  OR  REFRACTORY  ACUTE  LYMPHOBLASTIC  LEUKAEMIA  (r/r ALL) -- Approval Marks Kite’...

Source: pharmiweb.com
Related Topics:
United StatesSanta MonicaUnited KingdomFoster CityChristi ShawBrexucabtagene AutoleucelMaxs ToppGilead SciencesEuropean CommissionUniversity Hospital Of WuerzburgGilead Sciences IncSociety CanadaExchange CommissionGilead CompanyEuropean Medicines AgencyMarks KiteFourth IndicationTwo Cell TherapiesComplete RemissionMedian Overall SurvivalMore Than Two YearsAll PatientsAlmost Four YearsResponders DemonstratedUniversity Hospital
KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) RECEIVES POSITIVE CHMP OPINION IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL) - Vimarsana News

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) RECEIVES POSITIVE CHMP OPINION IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)

Published: July 22, 2022

KITE’S  CAR  T-CELL  THERAPY  TECARTUS®  (BREXUCABTAGENE  AUTOLEUCEL)  RECEIVES  POSITIVE  CHMP  OPINION  IN  RELAPSED  OR  REFRACTORY  ACUTE  LYMPHOBLASTIC  LEUKAEMIA  (r/r ALL) –  Tecartus® (Brex...

Source: pharmiweb.com
Related Topics:
United StatesSanta MonicaUnited KingdomFoster CityChristi ShawBrexucabtagene AutoleucelMaxs ToppGilead SciencesTreatment OptionsEuropean CommissionUniversity Hospital Of WuerzburgGilead Sciences IncExchange CommissionSociety CanadaGilead CompanyEuropean Medicines AgencyCommittee For Medicinal Products Human UseOnly Chimeric Antigen ReceptorReceive PositiveTreat AdultsSignificant Unmet NeedPatient PopulationLimited Treatment OptionsMedicinal ProductsHuman Use
Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting - Vimarsana News

Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting

Published: December 7, 2021

/PRNewswire/ -- Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...

Source: prnewswire.com
Related Topics:
United StatesSouth KoreaPerampanel MonotherapyIvan CheungChristopher VancheriManoj MalhotraUs Drug Enforcement AdministrationAmerican Epilepsy SocietyEisai IncEisai Co LtdNeurology Business GroupSustainable Development GoalsAmerican Epilepsy Society MeetingGlobal PresidentVice PresidentMedical AffairsExtension PhaseSafety Analysis SetScore StudyAdult Epilepsy Patients TreatedEveryday Clinical PracticeWorld ExperienceEpilepsy PatientsElderly Epilepsy PatientsPooled Analysis
Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting - Vimarsana News

Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting

Published: December 7, 2021

/PRNewswire/ -- Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...

Source: prnewswire.com
Related Topics:
United StatesSouth KoreaPerampanel MonotherapyIvan CheungChristopher VancheriManoj MalhotraUs Drug Enforcement AdministrationAmerican Epilepsy SocietyEisai IncEisai Co LtdNeurology Business GroupSustainable Development GoalsAmerican Epilepsy Society MeetingGlobal PresidentVice PresidentMedical AffairsExtension PhaseSafety Analysis SetScore StudyAdult Epilepsy Patients TreatedEveryday Clinical PracticeWorld ExperienceEpilepsy PatientsElderly Epilepsy PatientsPooled Analysis
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial - Vimarsana News

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

Published: October 1, 2021

In a phase 2 randomized placebo-controlled trial, Neil Formica and coauthors investigate the immunogenicity and safety of different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine in younger and older adults in USA and Australia.

Source: plos.org
Related Topics:
United KingdomUnited StatesNew ZealandSouth AfricaBaylor College Of MedicineMark AdamsTerry KleinFiona NapierPaul GriffinJason LickliterMark AryaCheryl KeechAmber LeahPaul NugentSusan ThackwrayNovavax GaithersburgIra BergerMark TurnerJoshua KimAstrazeneca OxfordCharlotte LemechPaul BradleyMary Beth ManningMaheshin RamasamyUniversity Of Oxford